Literature DB >> 30264629

Precision of T2 TSE MRI-CT-image fusions based on gold fiducials and repetitive T2 TSE MRI-MRI-fusions for adaptive IGRT of prostate cancer by using phantom and patient data.

D Wegener1, D Zips1,2, D Thorwarth3,2, J Weiß4, A E Othman4, U Grosse4, M Notohamiprodjo4, K Nikolaou4, A C Müller1.   

Abstract

INTRODUCTION: To increase precision of radiation treatment (RT) delivery in prostate cancer, MRI-based RT as well as the use of fiducials like gold markers (GMs) have shown promising results. Their combined use is currently under investigation in clinical trials. Here, we aimed to evaluate a workflow of image registration based on GMs between CT and MRI as well as weekly MRI-MRI adaption based on T2 TSE sequence.
MATERIAL AND METHODS: A gel-phantom with two inserted GMs was scanned with CT and three different MR-scanners of 1.5 and 3 T (T2 TSE and T1 VIBE-Dixon, isotropic, voxel size 2 × 2 × 2 mm). After image fusion, deviations for fiducial and gel match were measured and artifacts were evaluated. Additionally, CT-MRI-match deviations and MRI-MRI-match deviations of 10 Patients from the M-basePro study using GMs were assessed.
RESULTS: GMs were visible in all imaging modalities. The outer gel contours were matched with <1 mm deviation, contour volumes varied between 0 and 1%. The deviations of the GMs were less than 2 mm in any direction of MRI/CT. Shifts of peripherally or centrally located GMs were randomly distributed. The average MRI-CT-match precision of 10 patients with GMs was 1.9 mm (range 1.1-3.1 mm).
CONCLUSIONS: Match inaccuracies for GMs between reference CT and voxel-isotropic T2-TSE sequences are small. Spatial deviations of CT- and MR-contoured fiducials were less than 2 mm, i.e., below SLT of the applied modalities. In patients, the average CT-MRI-match precision for GMs was 1.9 mm supporting their use in MR-guided high precision RT.

Entities:  

Mesh:

Year:  2018        PMID: 30264629     DOI: 10.1080/0284186X.2018.1518594

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  7 in total

Review 1.  The Promise of Magnetic Resonance Imaging in Radiation Oncology Practice in the Management of Brain, Prostate, and GI Malignancies.

Authors:  Shashank Srinivasan; Archya Dasgupta; Abhishek Chatterjee; Akshay Baheti; Reena Engineer; Tejpal Gupta; Vedang Murthy
Journal:  JCO Glob Oncol       Date:  2022-05

2.  MR-PROTECT: Clinical feasibility of a prostate MRI-only radiotherapy treatment workflow and investigation of acceptance criteria.

Authors:  Emilia Persson; Christian Jamtheim Gustafsson; Petra Ambolt; Silke Engelholm; Sofie Ceberg; Sven Bäck; Lars E Olsson; Adalsteinn Gunnlaugsson
Journal:  Radiat Oncol       Date:  2020-04-09       Impact factor: 3.481

3.  Prospective evaluation of probabilistic dose-escalated IMRT in prostate cancer.

Authors:  Daniel Wegener; Bernhard Berger; Zhoulika Outtagarts; Daniel Zips; Frank Paulsen; Martin Bleif; Daniela Thorwarth; Markus Alber; Oliver Dohm; Arndt-Christian Müller
Journal:  Radiol Oncol       Date:  2020-12-22       Impact factor: 2.991

4.  Target definition in radiotherapy of prostate cancer using magnetic resonance imaging only workflow.

Authors:  Adalsteinn Gunnlaugsson; Emilia Persson; Christian Gustafsson; Elisabeth Kjellén; Petra Ambolt; Silke Engelholm; Per Nilsson; Lars E Olsson
Journal:  Phys Imaging Radiat Oncol       Date:  2019-03-20

5.  Investigation of the clinical inter-observer bias in prostate fiducial marker image registration between CT and MR images.

Authors:  Emilia Persson; Sevgi Emin; Jonas Scherman; Christian Jamtheim Gustafsson; Patrik Brynolfsson; Sofie Ceberg; Adalsteinn Gunnlaugsson; Lars E Olsson
Journal:  Radiat Oncol       Date:  2021-08-16       Impact factor: 3.481

6.  Influence of Urethra Sparing on Tumor Control Probability and Normal Tissue Complication Probability in Focal Dose Escalated Hypofractionated Radiotherapy: A Planning Study Based on Histopathology Reference.

Authors:  Simon K B Spohn; Ilias Sachpazidis; Rolf Wiehle; Benedikt Thomann; August Sigle; Peter Bronsert; Juri Ruf; Matthias Benndorf; Nils H Nicolay; Tanja Sprave; Anca L Grosu; Dimos Baltas; Constantinos Zamboglou
Journal:  Front Oncol       Date:  2021-05-14       Impact factor: 6.244

Review 7.  [Primary treatment of prostate cancer using 1.5 T MR-linear accelerator].

Authors:  Daniel Wegener; Daniel Zips; Cihan Gani; Simon Boeke; Konstantin Nikolaou; Ahmed E Othman; Haidara Almansour; Frank Paulsen; Arndt-Christian Müller
Journal:  Radiologe       Date:  2021-07-23       Impact factor: 0.635

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.